Product image of Nimotop (Nimodipine) supplied by GNH India

Nimotop

Active Ingredient:
Nimodipine
Origin:
EU

Nimotop (Nimodipine)

Nimodipine, the active ingredient in Nimotop, is a calcium channel blocker presented as an intravenous formulation for intravenous use. It is employed to prevent cerebral vasospasm following subarachnoid hemorrhage and to treat certain cerebrovascular disorders in adult patients. It is indicated for adult patients at risk of delayed cerebral ischemia and is administered under specialist supervision in acute care settings.

GNH India supplies Nimotop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Manufacturer / TM Owner

Laboratoire Xo

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Nimotop (nimodipine) acts on cerebral vasculature to prevent and treat vasospasm‑related complications.

  • Subarachnoid hemorrhage (post‑aneurysmal): reduces incidence of delayed cerebral ischemia by preventing vasospasm.
  • Cerebral vasospasm: provides sustained vasodilation to maintain cerebral blood flow.
  • Cerebrovascular disorders: supports neuroprotection in acute ischemic events.

How It Works

  • Nimodipine selectively blocks L‑type voltage‑gated calcium channels in smooth muscle cells of cerebral arteries. By inhibiting calcium influx, it induces dose‑dependent vasodilation of intracranial vessels, improving cerebral blood flow. The drug also stabilizes neuronal calcium homeostasis, offering neuroprotective effects against ischemic injury. The antagonism is relatively selective for cerebral vessels, sparing systemic circulation, which minimizes systemic hypotension. This property makes nimodipine suitable for use in patients with acute neurovascular injury.

Side Effects

Nimotop may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

  • Headache: mild to moderate intensity.
  • Hypotension: transient drop in blood pressure.
  • Nausea: occasional gastrointestinal upset.
  • Flushing: warmth and redness of skin.

Serious or Rare Side Effects

  • Severe hypotension: marked blood pressure fall requiring intervention.
  • Cardiac arrhythmia: abnormal heart rhythm.
  • Hepatotoxicity: elevated liver enzymes.
  • Allergic reaction: rash, pruritus, or anaphylaxis.

Precautions & Warnings

When using Nimotop, clinicians should observe specific safety measures.

  • Patient selection: use only in adults with confirmed subarachnoid hemorrhage or cerebrovascular risk.
  • Monitoring: observe blood pressure and neurological status regularly during infusion.
  • Concomitant vasodilators: avoid simultaneous use with other potent vasodilators to prevent excessive hypotension.
  • Liver function: assess hepatic function before initiation and monitor during therapy.
  • Pregnancy and lactation: contraindicated unless benefits outweigh risks; limited data available.
  • Store below 25°C: keep in original container, protect from light and moisture.

Avoid Interactions

Nimotop can interact with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid)

  • Other calcium channel blockers: additive vasodilatory effect may cause severe hypotension.
  • Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase nimodipine plasma levels, raising toxicity risk.
  • Nitrates: combined use can lead to profound hypotension.

Moderate Interactions (Monitor Closely)

  • CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy.
  • Antihypertensive agents: may enhance blood pressure lowering, requiring dose adjustment.
  • Diuretics: can potentiate hypotensive effect, monitor electrolytes.

Frequently Asked Questions

Nimotop contains the active ingredient nimodipine and is used primarily to prevent cerebral vasospasm after aneurysmal subarachnoid hemorrhage. It is also employed in the management of certain cerebrovascular disorders where improved cerebral blood flow and neuroprotection are desired.

Nimodipine selectively blocks L‑type calcium channels in the smooth muscle of cerebral arteries. This inhibition reduces calcium‑mediated contraction, causing vasodilation of intracranial vessels, which enhances cerebral perfusion and provides neuroprotective effects against ischemic injury.

The dosage of Nimotop is determined by the prescribing clinician based on the patient’s condition, weight, and clinical response. Specific dosing regimens are not disclosed here; healthcare professionals should refer to the product label and local prescribing guidelines.

Safety data for nimodipine in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Nimotop, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nimodipine is more selective for cerebral vessels than many other calcium channel blockers, which tend to affect systemic circulation. This selectivity reduces the risk of systemic hypotension, making nimodipine especially suitable for neurovascular indications such as subarachnoid hemorrhage.

Nimotop should be stored below 25 °C in its original packaging, protected from light and moisture. Avoid freezing the product. Follow standard aseptic handling procedures for intravenous preparations and discard any solution that appears discolored or contaminated.

Nimotop is supplied as an intravenous formulation and is administered by a healthcare professional under controlled conditions. The infusion rate and duration are set by the treating physician, who monitors the patient’s vital signs and neurological status throughout the administration.

Serious risks include severe hypotension, which can lead to organ hypoperfusion, cardiac arrhythmias, hepatotoxicity manifested by elevated liver enzymes, and hypersensitivity reactions ranging from rash to anaphylaxis. Prompt recognition and management of these events are essential.

Nimotop is contraindicated in patients with known hypersensitivity to nimodipine or any component of the formulation. It should also be avoided in individuals with severe uncontrolled hypotension or in those where the risk of vasodilation outweighs potential benefits, unless a physician decides otherwise.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Nimodipine

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT